Yaron Werber
Stock Analyst at TD Cowen
(1.27)
# 1,552
Out of 4,666 analysts
45
Total ratings
38.46%
Success rate
-11.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Initiates: Buy | n/a | $24.20 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $124.44 | +22.95% | 5 | Nov 15, 2024 | |
| BGNE BeiGene | Maintains: Buy | $254 → $260 | $187.77 | +38.47% | 6 | Nov 13, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $106.40 | +14.66% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $22.74 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $45.13 | +61.75% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $34.41 | -1.19% | 2 | Oct 21, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $54 → $59 | $33.75 | +74.81% | 1 | Jul 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $71 → $67 | $38.40 | +74.48% | 2 | Jul 15, 2024 | |
| STOK Stoke Therapeutics | Upgrades: Buy | n/a | $11.61 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.69 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.04 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.22 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $24.98 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $574.54 | +11.57% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.39 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.35 | +7,042.86% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $26.20 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $20.50 | +85.37% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.87 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.31 | - | 1 | Oct 26, 2021 |
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $24.20
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $124.44
Upside: +22.95%
BeiGene
Nov 13, 2024
Maintains: Buy
Price Target: $254 → $260
Current: $187.77
Upside: +38.47%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $106.40
Upside: +14.66%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $22.74
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $45.13
Upside: +61.75%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $34.41
Upside: -1.19%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $33.75
Upside: +74.81%
Legend Biotech
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $38.40
Upside: +74.48%
Stoke Therapeutics
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $11.61
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $20.69
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.04
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.22
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $24.98
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $574.54
Upside: +11.57%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.35
Upside: +7,042.86%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $26.20
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $20.50
Upside: +85.37%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.87
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.31
Upside: -